ASH 2012: Dr. Richard Furman Discusses What is Known and What Isn't About the New Treatments in Trials
He reviews the open pivotal for idelasilb (GS1101) and the associated crossovers, plus the trial for ibrutinib versus ofatumumab.
But there are other trials out there too that he didn't mention, especially for patients in special categories, such as 17p deletion or age > 65.
So always remember to check what clinical trials might be a fit for you at http://clinicaltrials.gov when you are considering treatment. Don't count on your doctor to know all the latest. See my prior post on clinical trials.
What I really like is the strategy he outlines of using these drugs one after another as stepping stones to a normal life expectancy.
More to come from ASH 2012.